Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBFβ/MYH11 after autologous transplantation: Undetectable fusion transcript in pretransplant progenitor cells

Katsuya Yamamoto, Shinichiro Nishikawa, Kentaro Minagawa, Kimikazu Yakushijin, Atsuo Okamura, Toshimitsu Matsui

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We describe here a unique case of therapy-related myelodysplastic syndrome (t-MDS) with inv(16)(p13q22) after autologous stem cell transplantation for lymphoma. The rare and smallest I type CBFβ/MYH11 fusion transcript with a breakpoint at nucleotide 399 of CBFβ and at nucleotide 2134 of MYH11 was detected in the bone marrow cells by reverse transcription polymerase chain reaction analysis. However, the fusion transcript was undetectable in the pretransplant peripheral blood stem cells. These results suggest that the stem cell damage leading to t-MDS may be induced mainly by the conditioning regimen for transplantation. Taken together with previous reports, the I type fusion transcript is preferentially induced with chemotherapy.

Original languageEnglish (US)
Pages (from-to)354-361
Number of pages8
JournalLeukemia Research
Volume30
Issue number3
DOIs
StatePublished - Mar 2006

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBFβ/MYH11 after autologous transplantation: Undetectable fusion transcript in pretransplant progenitor cells'. Together they form a unique fingerprint.

Cite this